Lowering the body temperature of organ donors following brain death in the intensive care unit may not improve how quickly transplanted organs begin to function, according to clinical evidence.
Understanding Solid Organ Transplantation and Donor Care Dynamics
Solid organ transplantation remains the optimal treatment for patients living with end-stage organ failure involving the kidney, heart, liver, lung, or pancreas. However, healthcare systems worldwide face a persistent shortage of optimal organs for donation. Because the process of brain death is known to cause significant injury to organs, optimizing donor management is critical to maximizing post-transplant graft function and recipient survival.
To mitigate this damage, clinicians have investigated targeted temperature management. Lowering the body temperature of donors below normal core temperatures—defined as less than 35.5°C—is hypothesized to slow the body’s processes and preserve organ viability until surgical retrieval occurs. This intervention can be achieved via spontaneous cooling, fans, ice packs, bladder irrigation, invasive cooling lines, or temperature-controlled humidified ventilator gases. Depending on the target, hypothermia is categorized as mild (34.0°C to 35.5°C), moderate (32.0°C to 33.9°C), moderately deep (30.0°C to 31.9°C), or deep (below 30°C).
In Plain English: The Clinical Takeaway
- Targeted Cooling: Cooling organ donors below normal body temperature does not appear to speed up how soon a newly transplanted kidney, liver, or lung starts working in the recipient.
- Organ Supply and Safety: Lowering donor body temperature is safe—it does not increase heart issues for the donor or reduce the total number of organs successfully recovered for transplantation.
- Evidence Gaps: Current clinical data rarely track long-term recipient metrics like 12-month quality of life, specific heart function, or ongoing insulin requirements for pancreas recipients.
Clinical Evidence and Comparative Organ Outcomes
Evaluating the true efficacy of donor temperature management requires rigorous studies. Reviews incorporating data from international centers, primarily across the United States and France, have pooled findings from four studies encompassing 2,096 donors and thousands of recipients. These investigations assessed whether actively cooling donors improved how soon donated organs started working, transplantation success rates, and recipient survival.
For kidney transplantation, analyzing data across four studies involving 3,015 recipients demonstrated that donor cooling does not reduce the time it takes for transplanted kidneys to start working. Furthermore, data covering 2,075 kidney recipients across three studies indicated no difference in one-year graft survival rates. Survival rates for kidney recipients at the one-year mark similarly showed no difference between cooled and normothermic control groups in one study involving 526 recipients.
For extra-renal organs, findings remain similarly nuanced. Data from individual studies tracking lung and liver recipients (99 and 262 recipients, respectively) revealed that donor hypothermia does not reduce the time for transplanted lungs or livers to start to work. However, across four studies encompassing 4,265 recipients, targeted temperature management proved unlikely to reduce the number of organs available for transplant. Importantly, safety evaluations involving 2,015 donors across three studies confirmed that lowering core body temperature does not cause problems with the donors, such as heart issues.
| Clinical Parameter | Impact of Donor Cooling vs. Normothermia | Supporting Evidence Base |
|---|---|---|
| Kidney Graft Function | No significant reduction in time to initial function | 4 studies, 3,015 recipients |
| 1-Year Kidney Survival | No significant difference in graft or recipient survival | 3 studies, 2,075 recipients (graft); 1 study, 526 recipients (patient) |
| Liver and Lung Recovery | Does not accelerate time to initial organ function | 1 study (lung, 99 recipients); 1 study (liver, 262 recipients) |
| Organ Availability & Donor Safety | Does not reduce organ yield; does not increase donor cardiac risk | 4 studies, 4,265 recipients (availability); 3 studies, 2,015 donors (safety) |
Methodological Limitations and Research Horizons
Despite aggregate patient numbers, critical evidence gaps persist in transplant medicine. The primary limitation of current literature is the small number of studies investigated and the donor organs transplanted, with most studies focusing on kidney donors and recipients, leaving non-renal organs such as the heart, lungs, and pancreas underrepresented. Additionally, long-term prognostic markers remain underreported.
Contraindications & When to Consult a Doctor
Families of potential donors or organ transplant recipients with questions regarding perioperative management protocols should consult directly with their medical team to review institutional policies and evidence-based care plans.
